Appendix 6.1 Steroid injection

Study	Inclusion/exclusion crite	eria and diagnosis of FS	Participant characteristics (age, sex, diabetes)	Condition-related characteristics (duration and stage of FS, previous treatments, secondary FS)
RCT Country, setting and treatment provider: Turkey; physical therapy and rehabilitation department of a hospital	and passive movements of directions; aged 18–70 ye 6 months; and no treatme	0 ,	Age (years), mean (SD): Steroid injection: 56.9 (9.56); placebo injection: 56.3 (8.16) Female: 44% Participants with diabetes? Unclear/ not reported	Duration of FS at baseline: NR Stage of FS at baseline: NR Previous treatments for FS: NR Participants with secondary FS: None reported
Intervention 1 Steroid injection: intra-articular, posterior approach injection of methylprednisolone acetate, 40 mg, 1 ml. One injection only. 5-cm 21-gauge needle Home exercise	Intervention 2	Intervention 3	Control Placebo injection: intra-articular, posterior approach injection of saline, 0.9% sodium chloride, 1 ml. One injection only. 5-cm 21-gauge needle Home exercise	Concomitant treatment and details of home exercise Oral paracetamol (1500 mg/day) was recommended to patients when needed Home exercise: Five sessions daily for 12 weeks (420 sessions in total) of home exercise consisting of pendulum circumduction and passive shoulder self-stretching in forward elevation, external rotation, horizontal adduction and internal rotation. When passive range of movement reached 90% of normal range the following exercises were added: isometric in all planes, theraband exercises (low, medium and high resistance), strengthening exercises for scapular stabilising muscles, and advanced muscle strengthening exercises with dumb-bells. Participants were advised to apply a heat pack before exercise

DOI: 10.3310/hta16110

Inclusion/exclusion criteria and dia	agnosis of FS	Participant characteristics (age, sex, diabetes)	Condition-related characteristics (duration and stage of FS, previous treatments, secondary FS)
pain with limitation of both active and glenohumeral joint of ≥ 25% in at lea external rotation, internal rotation) col with normal values. Patients eligible for adhesive capsulitis and were aged for < 1 year and had a total SPADI sc patients with diabetes mellitus becam Exclusion criteria: Adhesive capsulitis including inflammatory, degenerative cerebrovascular accident or fracture. allergy to radiological contrast materi. Method of diagnosis: Presence of pai	I passive movements of the st two directions (abduction, flexion, mpared with contralateral shoulder or or inclusion if they met the definition d ≥ 18 years, had been symptomatic ore of ≥ 30. Partway through the trial ne eligible to be included secondary to another cause, metabolic or infectious arthritis, Known blood coagulation disorder or all nand range of movement	Age (years), mean (SD): Steroid injection + PT: 54.9 (10.5); steroid injection: 55.4 (10.0); PT: 54.2 (8.3); placebo injection: 56.5 (9.4) Female: 59% Any participants with diabetes? Yes. Steroid injection + PT: n = 2 (9.5%); steroid injection: n = 1 (4.3%); PT: n = 1 (3.9%); placebo injection: n = 2 (8.7%)	Duration of FS at baseline (weeks), mean (SD): Steroid injection + PT: 22.1 (14.9); steroid injection: 21.2 (11.0); PT: 20.8 (11.2); placebo: 20.3 (7.3) Stage of FS at baseline: NR Previous treatments for FS: NR Participants with secondary FS: None reported
Intervention 2	Intervention 3	Control	Concomitant treatment and details of home exercise
Steroid injection: Steroid injection as in combined intervention. Home exercise	PT+placebo injection: Injection of saline, 2 ml into shoulder joint space using fluoroscopic guidance. One injection on day of randomisation only. PT only as in combined intervention Home exercise	Placebo injection: Injection of saline, 2 ml into shoulder joint space using fluoroscopic guidance. One injection on day of randomisation only Home exercise	Patients were given a supply of paracetamol tablets. All other medications for the treatment of adhesive capsulitis were stopped Home exercise: Home exercises of active and auto-assisted range of movement exercises in the planes of flexion, abduction, external rotation and internal rotation, 10 minutes twice daily for 12 weeks
	Inclusion criteria: Adhesive capsulitis pain with limitation of both active and glenohumeral joint of ≥ 25% in at lea external rotation, internal rotation) coi with normal values. Patients eligible f for adhesive capsulitis and were aged for <1 year and had a total SPADI so patients with diabetes mellitus becam Exclusion criteria: Adhesive capsulitis including inflammatory, degenerative cerebrovascular accident or fracture. allergy to radiological contrast materi Method of diagnosis: Presence of pai Condition terminology used: Adhesive Intervention 2 Steroid injection: Steroid injection as in combined intervention.	Steroid injection: Steroid injection as in combined intervention. Home exercise PT + placebo injection: Injection of saline, 2 ml into shoulder joint space using fluoroscopic guidance. One injection on day of randomisation only. PT only as in combined intervention	Inclusion/exclusion criteria and diagnosis of FS Inclusion criteria: Adhesive capsulitis defined as the presence of shoulder pain with limitation of both active and passive movements of the glenohumeral joint of ≥ 25% in at least two directions (abduction, flexion, external rotation, internal rotation) compared with contralateral shoulder or with normal values. Patients eligible for inclusion if they met the definition for adhesive capsulitis and were aged ≥ 18 years, had been symptomatic for < 1 year and had a total SPADI score of ≥ 30. Partway through the trial patients with diabetes mellitus became eligible to be included Exclusion criteria: Adhesive capsulitis secondary to another cause, including inflammatory, degenerative, metabolic or infectious arthritis, cerebrovascular accident or fracture. Known blood coagulation disorder or allergy to radiological contrast material Method of diagnosis: Presence of pain and range of movement Condition terminology used: Adhesive capsulitis Intervention 2 Intervention 3 Control Placebo injection: Injection: Injection: Injection of saline, 2 ml into shoulder joint space using fluoroscopic guidance. One injection on day of randomisation only. PT only as in combined intervention. Home exercise Intervention 2 Intervention 3 Control

Study	Inclusion/exclusion criteria and d	liagnosis of FS	Participant characteristics (age, sex, diabetes)	Condition-related characteristics (duration and stage of FS previous treatments, secondary FS)
Dacre 1989 ⁶⁷ RCT Country, setting and treatment provider: UK; physiotherapy was performed by a physiotherapist, the steroid was injected by a physician	Inclusion criteria: Criteria of Bulgen least 4 weeks; inability to use arm v	et al. (1984): painful stiff shoulder for at with restriction of movement and loss of leep disturbance and inability to lie on disposing conditions were excluded osis (examination, radiography and	Age (years), mean: Steroid injection: 55.8; PT: 53.0; steroid injection + PT: 58.8 Female: 55% Any participants with diabetes? Yes. n=3	Duration of FS at baseline: NR Stage of FS at baseline: NR Previous treatments for FS: NR Participants with secondary FS: None reported
Intervention 1	Intervention 2	Intervention 3	Control	Concomitant treatment and details of home exercise
Steroid injection + PT: 20 mg triamcinolone with 1 ml 2% lidocaine was injected anteriorly. Mobilisation was the mainstay of physiotherapy (4–6 weeks' duration). The specific method was chosen by the physiotherapist	Steroid injection: 20 mg triamcinolone with 1 ml 2% lidocaine was injected anteriorly	PT: Mobilisation was the mainstay of physiotherapy (4–6 weeks' duration)		NR
Study	Inclusion/exclusion criteria and d	liagnosis of FS	Participant characteristics (age, sex, diabetes)	Condition-related characteristics (duration and stage of FS, previous treatments, secondary FS)
Rizk 1991 ⁴² RCT Country, setting and treatment provider: USA; one physician performed all injections	effusion in the glenohumeral joint, n injections in the involved shoulder, r or steroids, absence of polyarthritis shoulder pain, no evidence of altern	ths, nocturnal accentuation of pain, no to history of recent trauma, no previous to history of allergy to local anaesthetics or neurological disease that cause ative causes of shoulder pain revealed at of pain and within 2 months of study amptoms	Age (years), mean (range): Total: 55 (40–70); steroid (anterior) + lidocaine + PT: 55.9; steroid (lateral) + lidocaine + PT: 52.3; lidocaine (anterior) + PT: 57.7; lidocaine (lateral) + physiotherapy: 54.1 Female: 41.7% Any participants with diabetes? Unclear/NR	Duration of FS at baseline (weeks), mean (range): Total: 13.2 (8 to 18) Stage of FS at baseline: NR Previous treatments for FS: NR Participants with secondary FS: None reported

DOI: 10.3310/hta16110

Intervention 1	Intervention 2	Intervention 3	Control	Concomitant treatment and details of home exercise
Steroid (anterior approach) + PT: Once a week for 3 weeks intra- articular injection using the anterior approach (glenohumeral joint) of 1 ml repository aqueous suspension of methylprednisolone acetate (Depo-Medrol®), 40 mg/ml with 2 ml of 1% lidocaine. 1.5-inch, 21-gauge needle. Standardised weekly PT treatment for 11 weeks. Ultrasonic therapy of 1.5W/cm² for 7 minutes followed by therapeutic exercise (Codman and wall climbing) Home exercise	Steroid (lateral approach) + PT: Same as for intra-articular steroid except using lateral approach (subacromial bursa) Home exercise	Two arms for placebo injection: intra-articular lidocaine (anterior approach) + PT: Once a week for 3 weeks intra-articular injection using the anterior approach of 1% lidocaine. 1.5-inch, 21-gauge needle. PT as for steroid group; intrabursal lidocaine (lateral approach) + PT: Once a week for 3 weeks intrabursal injection using the lateral approach of 1% lidocaine. 1.5-inch, 21-gauge needle. PT as for steroid group. Home exercise		Advised to continue NSAIDs prescribed by physician. All patients were receiving NSAIDs, with only minor difference in frequency distribution of various drugs between the treatment groups. Propoxyphene and other drugs were discontinued before entry into the study Home exercise: Instruction given in a home exercise programme (no further details provided)
Study	Inclusion/exclusion criteria and dia	agnosis of FS	Participant characteristics (age, sex, diabetes)	Condition-related characteristics (duration and stage of FS, previous treatments, secondary FS)
Ryans 2005 ⁴¹ RCT Country, setting and treatment provider: UK; direct access shoulder assessment clinic run by a GP with a special interest in rheumatology at a local district hospital. Injections provided by the same experienced clinician, physiotherapy provided by a single therapist or a nominated deputy if unavailable	Inclusion criteria: Aged ≥ 18 years wi cervical (C5) dermatone distribution of duration; presence of restriction of act in both external rotation and glenohus with other shoulder. Exclusion criteria: Previous intra-artic physiotherapy for this episode of shour rotation or glenohumeral abduction; on radiography; clinical evidence of rotariuma to the shoulder or history of in a cerebrovascular accident affecting capsulitis; patients with a contraindic Method of diagnosis: Radiography Terminology used: Adhesive capsulitis	of > 4 weeks' and < 6 months' etive and passive range of movement meral abduction of > 25% compared etilar injection or previous ulder pain; limitation in only external evidence of glenohumeral osteoarthritis otator cuff tear; history of significant inflammatory joint disease or of the shoulder; bilateral adhesive aution to triamcinolone	Age (years), mean (SD): Steroid injection + PT: 56.3 (6.4); steroid injection: 52.3 (9.3); PT + placebo injection: 52.6 (7.7); placebo injection: 55.2 (9.4) Female: 59% Any participants with diabetes? Yes. Total: n=5; steroid injection + PT: n=1 (5%); steroid injection: n=1 (5%); PT + placebo injection: n=1 (5%); placebo injection: n=(11%)	Duration of FS at baseline (weeks), mean (SD): Steroid injection + PT: 14.2 (4.4); steroid injection: 12.2 (5.3); PT + placebo injection: 14.4 (4.4); placebo injection: 14.9 (3.7) Stage of FS at baseline: NR Previous treatments for FS: NR Participants with secondary FS: Unclear; 32% were reported to have experienced 'minor trauma'. No further details were provided

Steroid injection + PT: Injection of triamcinolone 20 mg, 1 ml and normal saline 2 ml using a combined non-guided approach to the shoulder: intra-articular, 1.5 ml injected by an anterior approach and 1.5 ml by a lateral approach. Physiotherapy consisted of eight sessions over 4 weeks: proprioceptive neuromuscular facilitation, Maitland mobilisations (which were progressed as the condition improved), standardised interferential modality and active exercise therapy with gym equipment Steroid injection only: Injection of triamcinolone 20 mg, 1 ml and normal saline 2 ml using a combined non-guided approach to Placebo injection: Placebo injection: Placebo injection: Injection of saline 3 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a combined non-guided approach to the shoulder: 1.5 ml using a valeral approach
Home exercise

FS, frozen shoulder; NR, not reported; PT, physiotherapy.